Allegheny Health Network and START partner to expand early-phase cancer trials in Western Pennsylvania

The collaboration will establish a START clinical trial site inside AHN’s Allegheny General Hospital, connecting patients across the region with START’s portfolio of nearly 1,000 active early-phase oncology studies.

Allegheny Health Network (AHN) and The START Center for Cancer Research have entered a strategic collaboration to establish a new early-phase oncology clinical trial site within the AHN Cancer Center at Allegheny General Hospital in Pittsburgh. 

The site will become part of START’s international research network and provide AHN patients with local access to its portfolio of industry-sponsored early-phase cancer trials, reducing the need for patients to travel outside Western Pennsylvania to participate.

Field	Content
Alert Type	Deal
Companies	Allegheny Health Network (AHN); The START Center for Cancer Research (START)
Deal Type	Strategic clinical research collaboration
Asset or Company	New START early-phase oncology clinical trial site at the AHN Cancer Center
Therapy Area(s)	Oncology; Cancer
Technology or Modality	Early-phase clinical trials; Investigational oncology therapies
Deal Value	Financial terms were not disclosed.
Development Stage	Early-phase clinical development
Geography	Western Pennsylvania, United States
What Happened	On 25 August 2026, AHN and START announced a strategic collaboration to establish a dedicated START early-phase clinical trial site within the AHN Cancer Center at Allegheny General Hospital in Pittsburgh. The site will be fully integrated into START’s network and will have access to its global trial portfolio from launch. The collaboration combines START’s early-phase oncology research infrastructure with AHN’s existing cancer specialists and clinical-care network. (www.ahn.org)
Why It Matters	Patients in Western Pennsylvania have historically had limited local access to community-based early-phase oncology studies, potentially requiring travel to participate. Embedding a dedicated trial site within AHN means eligible patients can potentially access investigational treatments as part of their existing cancer-care pathway, reducing a practical barrier to trial participation. Pennsylvania records approximately 89,000 new cancer cases annually, according to the organisations. (www.ahn.org)
Supporting Context	AHN is a 16-hospital health system, while its Cancer Center employs more than 200 physicians and 500 oncology professionals across 24 affiliated oncology clinics and serves more than 20,000 new patients annually. START operates across 16 locations in the US and Europe, with more than 40 principal investigators and nearly 1,000 active studies. (www.ahn.org)
Strategic Rationale	START gains access to AHN’s substantial regional cancer population and established clinical infrastructure, extending its community-based trial network into Western Pennsylvania. AHN gains a dedicated early-phase research capability and access to START’s international portfolio of industry-sponsored trials, strengthening the range of investigational treatment opportunities it can offer patients.
Potential Impact	The collaboration could increase participation in early-phase oncology trials across Western Pennsylvania and neighbouring regions while giving biopharma sponsors another community-based site through which to recruit patients. Its impact will ultimately depend on the studies activated at the new centre, patient eligibility and enrolment.
Key Takeaway	AHN is bringing START’s early-phase oncology trial network directly into its flagship cancer centre, creating a new local route into investigational cancer studies for patients across Western Pennsylvania.
What to Watch	Opening of the new START site, the first studies activated at Allegheny General Hospital, patient enrolment levels and whether the partnership expands the range and volume of early-phase oncology trials available through AHN.
Primary Source	Allegheny Health Network / The START Center for Cancer Research (www.ahn.org)
Relevant Date	25 August 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com